Rosenberg Matthew Hamilton Sells 405 Shares of AstraZeneca PLC (NASDAQ:AZN)

Rosenberg Matthew Hamilton lessened its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 26.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,135 shares of the company’s stock after selling 405 shares during the period. Rosenberg Matthew Hamilton’s holdings in AstraZeneca were worth $74,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Meeder Advisory Services Inc. bought a new position in shares of AstraZeneca during the second quarter worth about $206,000. Brown Brothers Harriman & Co. grew its stake in shares of AstraZeneca by 3.7% during the 2nd quarter. Brown Brothers Harriman & Co. now owns 6,062 shares of the company’s stock worth $473,000 after acquiring an additional 216 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of AstraZeneca by 62.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 27,329 shares of the company’s stock worth $2,131,000 after acquiring an additional 10,500 shares in the last quarter. Sofinnova Investments Inc. raised its holdings in shares of AstraZeneca by 34.3% in the second quarter. Sofinnova Investments Inc. now owns 801,417 shares of the company’s stock valued at $62,503,000 after purchasing an additional 204,704 shares during the last quarter. Finally, Wealth Alliance lifted its position in shares of AstraZeneca by 5.9% in the second quarter. Wealth Alliance now owns 17,440 shares of the company’s stock worth $1,360,000 after purchasing an additional 975 shares in the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

AZN has been the subject of a number of analyst reports. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, AstraZeneca currently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Stock Performance

Shares of AZN stock opened at $65.37 on Wednesday. The stock has a market cap of $202.69 billion, a P/E ratio of 31.28, a P/E/G ratio of 1.19 and a beta of 0.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71. The company has a fifty day moving average price of $65.98 and a two-hundred day moving average price of $74.69. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. The company had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. AstraZeneca’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.87 EPS. As a group, equities analysts predict that AstraZeneca PLC will post 4.11 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.